Company Overview and News

1
Veritas Pharma Announces Loan to Marapharm and Cancellation of Stock Options

2018-07-27 globenewswire - 1
VANCOUVER, British Columbia, July 27, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that effective June 25, 2018, it cancelled a total of 3,272,000 incentive stock options (“Options”) granted under the Company’s stock option plan (the “Option Plan”) to consultants, directors of the Company. The cancelled Options were voluntarily surrendered by the holder thereof for no consideration.
VRT MDM VRTHF MRPHF

 
SHARC Wins Canadian Prestigious Water Canada’s Industry Award

2018-07-09 globenewswire
VANCOUVER, British Columbia, July 09, 2018 (GLOBE NEWSWIRE) -- Sharc International Systems Inc. (CSE:SHRC) (FSE:IWIA) (OTCQB:INTWF) ("SHARC" or "the Company") is pleased to announce that the Company’s revolutionary SHARC™ wastewater heat exchange system has won three top awards at the prestigious Water’s Next Award program that honours the achievements of individuals and companies that successfully improve freshwater in Canada.
LEDIF VRT MDM VRTHF AQSZF LMD MRPHF AQS

20
Stamper Oil & Gas Provides Corporate Update

2018-04-11 globenewswire
VANCOUVER, British Columbia, April 11, 2018 (GLOBE NEWSWIRE) -- Stamper Oil & Gas Corp. (TSX-V:STMP) (FSE:TMP2) (OTCQB:STMGF) (“Stamper” or “the Company”), is pleased to provide an update to its current and prospective Stamper Shareholders regarding the Company for the first three months of 2018.
VRT MDM VRTHF ABCO MRPHF

10
Stamper Oil & Gas Announces the Appointment of David M. Alexander CPA, CA as CFO

2018-03-27 globenewswire
VANCOUVER, British Columbia, March 27, 2018 (GLOBE NEWSWIRE) -- Stamper Oil & Gas Corp. (TSX-V:STMP) (FSE:TMP2) (OTCQB:STMGF) (“Stamper” or “the Company”) today is pleased announce the appointment of David M. Alexander, CPA, CA as Chief Financial Officer of the Company, to take effect on April 1st, 2018. Mr. Alexander replaces Mr. Omair Choudhry as CFO. Stamper thanks Mr. Choudhry for his services and dedication while in the role of CFO of the Company.
VRT MDM VRTHF COM MRPHF CRME

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CNSX:MDM / Marapharm Ventures Inc. on message board site Silicon Investor.

Mountain Province Diamonds MDM MPV Mountain Province Diamonds MDM MPV Mountain Province Diamonds MDM MPV MDMI - Italian Bakery Extraordinaire! MDMI - Italian Bakery Extraordinaire! MDMI - Italian Bakery Extraordinaire!
MedPartners (MDM) MedPartners (MDM) MedPartners (MDM) Medirisk -- MDMD, is looking good!!!!! Medirisk -- MDMD, is looking good!!!!! Medirisk -- MDMD, is looking good!!!!!
Massimou0027s Bakery (MDMI) Massimou0027s Bakery (MDMI) Massimou0027s Bakery (MDMI) Massimou0027s Bakery - Java Centrale (MDMI) Massimou0027s Bakery - Java Centrale (MDMI) Massimou0027s Bakery - Java Centrale (MDMI)
MDMI...The Little Italian Bakery that Could MDMI...The Little Italian Bakery that Could MDMI...The Little Italian Bakery that Could MDMI: Massimo da Milano, Inc. at .02 up 66% 52wk high .38 MDMI: Massimo da Milano, Inc. at .02 up 66% 52wk high .38 MDMI: Massimo da Milano, Inc. at .02 up 66% 52wk high .38